News
Platinum Add-On Improves Survival in Early TNBC
- Author:
- M. Alexander Otto, PA, MMS
Trial outcomes provide strong evidence for incorporating carboplatin into both the neoadjuvant and adjuvant settings in patients with early-stage...
News
FDA Expands Durvalumab Label to Endometrial Cancer
- Author:
- M. Alexander Otto, PA, MMS
Approval of the new indication was based on the phase 3 DUO-E trial, which included women with newly diagnosed advanced or recurrent dMMR...
News
FDA Expands Repotrectinib Label to All NTRK Gene Fusion+ Solid Tumors
- Author:
- M. Alexander Otto, PA, MMS
The approval was based on a single-arm open-label trial in 88 adults with locally advanced or metastatic NTRK gene fusion solid tumors....
News
‘Practice Changing’ Results for Osimertinib in Unresectable Stage III EGFR+ NSCLC
- Author:
- M. Alexander Otto, PA, MMS
Study results, including extended median PFS of 33.5 months, are expected to lead to approval in unresectable stage III disease.
News
The ASCO Annual Meeting Starts This Week
- Author:
- M. Alexander Otto, PA, MMS
More than 7000 abstracts were submitted for this year’s meeting a new record — and over 5000 were selected for presentation.
News
Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It?
- Author:
- M. Alexander Otto, PA, MMS
Oncologists expressed serious doubts about whether the potential benefits of irinotecan liposome are worth the extra cost.
News
FDA Approves Tarlatamab for Extensive-Stage Small Cell Lung Cancer
- Author:
- M. Alexander Otto, PA, MMS
Approval was based on data from 99 patients in the DeLLphi-301 trial with relapsed/refractory extensive-stage SCLC who had progressed after...
News
FDA Broadens Breyanzi’s Follicular Lymphoma Indication
- Author:
- M. Alexander Otto, PA, MMS
For adults with relapsed/refractory follicular lymphoma, the FDA has approved an expanded indication for Breyanzi.
News
Potential Cure for Early BRCA-Mutated Breast Cancer?
- Author:
- M. Alexander Otto, PA, MMS
All patients who recieved a combination of standard chemotherapy with olaparib were alive at 36 months.
News
FDA Approves Second Gene Therapy for Hemophilia B
- Author:
- M. Alexander Otto, PA, MMS
For adults with hemophilia B, a second gene therapy — also priced at $3.5 million — has been greenlighted by the Food and Drug Administration.
News
Is Osimertinib Better Alone or With Chemotherapy in Non–Small Cell Lung Cancer?
- Author:
- M. Alexander Otto, PA, MMS
Randomized trial of 557 patients compares taking osimertinib alone to osimertinib with pemetrexed plus cisplatin or carboplatin, followed by...
News
Has Immunotherapy Found Its Place in Pancreatic Cancer?
- Author:
- M. Alexander Otto, PA, MMS
Study examines whether immunotherapy has a role in the neoadjuvant setting before surgery.
News
Ovarian Cancer: Another Promising Target for Liquid Biopsy
- Author:
- M. Alexander Otto, PA, MMS
A test under development “looks very sensitive for detecting ovarian cancer early.”
News
What to Know About the Next-Gen FIT for CRC Screening
- Author:
- M. Alexander Otto, PA, MMS
These multitarget approaches take the standard FIT a step further by testing for additional DNA, RNA, or protein biomarkers associated with CRC to...
News
Liquid Biopsy Has Near-Perfect Accuracy for Early Pancreatic Cancer
- Author:
- M. Alexander Otto, PA, MMS
Researchers develop signature for pancreatic cancer based on microRNAs and cell-free DNA markers in the blood of patients with the disease.